Chittaranjan National Cancer Institute is a cancer care hospital & Research Institute and one of the 25 Regional Cancer Centres in India. It is located in Kolkata near Jatin Das Park metro station at Hazra More.

During the past decade, Chittaranjan National Cancer Institute conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chittaranjan National Cancer Institute" #1 sponsor was "Bayer" with 1 trials, followed by "Boehringer Ingelheim" with 1 trials sponsored, "Cadila Pharnmaceuticals" with 1 trials sponsored, "Merck KGaA, Darmstadt, Germany" with 1 trials sponsored and "Morphotek" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chittaranjan National Cancer Institute" #1 collaborator was "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator, "James Graham Brown Cancer Center" with 1 trials as a collaborator, "Merck Ltd., India" with 1 trials as a collaborator, "THINQ Pharma CRO Ltd." with 1 trials as a collaborator and "Unique Pharmaceuticals Ltd, India" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Chittaranjan National Cancer Institute" are "Cervical Cancer" (1 trials), "Chronic Myeloid Leukemia (for Part B and C)" (1 trials), "Colorectal Neoplasms" (1 trials), "Glioblastoma Multiforme" (1 trials) and "Healthy (For Part A)" (1 trials). Many other conditions were trialed in "Chittaranjan National Cancer Institute" in a lesser frequency.

Most popular intervention types in "Chittaranjan National Cancer Institute" are "Drug" (8 trials), "Biological" (2 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "BAY2757556 (Larotrectinib, Vitrakvi)" (1 trials), "Bevacizumab as Avastin" (1 trials), "Bevacizumab as MYL-1402O" (1 trials), "Carboplatin" (1 trials) and "Cetuximab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Chittaranjan National Cancer Institute" are 8 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Chittaranjan National Cancer Institute". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Chittaranjan National Cancer Institute, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Chittaranjan National Cancer Institute, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".